Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7388934 | Value in Health | 2018 | 8 Pages |
Abstract
Our study suggests that the WAC may be an overestimate for the base case because the minimum WAC is higher than the NADAC for most drugs. Our approach balances uncertainty and lack of data for the cost of pharmaceuticals with the need for a transparent and consistent approach for valid CEAs.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Joseph BS, Marjorie PhD, FSA, David PhD,